SLC22A18抗体;SLC22A18 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P13191(SLC22A18 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The SLC22A18 antibody targets the protein encoded by the *SLC22A18* gene, a member of the solute carrier family 22 (SLC22) involved in transmembrane transport of organic ions and metabolites. Located on chromosome 11p15.5. this gene resides in a genomic region associated with imprinting disorders and tumorigenesis. SLC22A18. also known as ORCTL2 or BWR1A, is proposed to function as a tumor suppressor, with roles in regulating cell proliferation, apoptosis, and metabolic processes. Epigenetic silencing or loss of heterozygosity at this locus has been linked to cancers, including pediatric tumors (e.g., Wilms' tumor) and adult carcinomas.

The SLC22A18 antibody is widely used in research to study protein expression, subcellular localization (e.g., plasma membrane or cytoplasmic distribution), and its interaction with signaling pathways in both normal and diseased tissues. It serves as a critical tool in immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) to explore tissue-specific expression patterns and dysregulation in malignancies. Studies utilizing this antibody have also investigated its potential role in drug transport and metabolic diseases. Despite its importance, challenges remain in fully elucidating its substrate specificity and regulatory mechanisms. Ongoing research aims to clarify its diagnostic or therapeutic relevance in oncology and metabolic disorders.